CAY10502
Based on 1 Customer Validation
CAY10502 is a potent, calcium-dependent cytosolic phospholipase A2 α (cPLA2α) inhibitor with an IC50 of 4.3 nM for isolated enzyme. CAY10502 can be used in the research of retinopathy and inflammatory diseases.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.72%
- CAS. Nr.: 888320-29-4
- Formel: C30H37NO7
- Molecular Weight:523.62
-
Speicherung:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Lipid Metabolism Compound Library
HY-L091
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Immunology/Inflammation Compound Library
HY-L007
Alle Phospholipase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
cPLA2α 4.3 nM (IC50) |
CAY10502 inhibits the release of arachidonic acid mediated by cPLA2R stimulanted with A23187 and TPA in human platelets, with IC50s of 0.57 and 0.0009 μM, respectively[1].
CAY10502 (5, 20, 50 nM; 12 hours; müller cells) inhibits normoxic- and hypoxia-induced Prostaglandin E2 (PGE2) and VEGF production[2].
CAY10502 (0.1-100 nM; 24 hours) inhibits the VEGF-induced proliferation of rat retinal microvascular endothelial cells (RRMEC)[2].
CAY10502 (10 μM) inhibits arachidonic acid (AA) release from the phospholipid pools, abrogated extremely low-frequency electromagnetic fields (ELF-EMF; 1 h) induced AA increase and the ELF-EMF inhibitory effect of Cav3.2 channels[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RRMEC
-
Concentration:0.1-100 nM
-
Incubation Time:24 hours
-
Result:CAY10502 (35, 50 nM) demonstrated significant reductions in VEGF-induced proliferation (64.3% and 84.1%, respectively) compared with cultures treated with VEGF alone.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:OIR and room air (RA) Sprague-Dawley rat[2]
-
Dosage:2.5, 25, 100 nM; 5 μL
-
Administration:Intravitreal Injection
-
Result:Injection of 100 nM CAY10502 resulted in a 53.1% reduction in NV compared with vehicle treatment.
Chemical Information
-
CAS. Nr. 888320-29-4
-
Appearance Solid
-
Molecular Weight 523.62
-
Formel C30H37NO7
-
Color White to off-white
-
SMILES
O=C(C1=CN(CC(COC2=CC=C(OCCCCCCCCCC)C=C2)=O)C3=C1C=C(C(O)=O)C=C3)OC
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 12.5 mg/mL (23.87 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Pohjala L L, et al. Interference by bovine serum albumin in PED6 based phospholipase A2 screening assays[J]. Die Pharmazie, 2012. [Content Brief]
[2]. Barnett JM, et al. Role of cytosolic phospholipase A(2) in retinal neovascularization. Invest Ophthalmol Vis Sci. 2010;51(2):1136-1142. [Content Brief]
[3]. Cui Y, et al. Exposure to extremely low-frequency electromagnetic fields inhibits T-type calcium channels via AA/LTE4 signaling pathway. Cell Calcium. 2014 Jan;55(1):48-58. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9098 mL | 9.5489 mL | 19.0978 mL | 47.7445 mL |
| 5 mM | 0.3820 mL | 1.9098 mL | 3.8196 mL | 9.5489 mL | |
| 10 mM | 0.1910 mL | 0.9549 mL | 1.9098 mL | 4.7745 mL | |
| 15 mM | 0.1273 mL | 0.6366 mL | 1.2732 mL | 3.1830 mL | |
| 20 mM | 0.0955 mL | 0.4774 mL | 0.9549 mL | 2.3872 mL |
CAY10502 Related Classifications
HY-116301 Related Classifications
Powered by Bioz